1. Scrip
  2. >>Therapy Areas
  3. >>Dermatological

Domain/Rusnano starts, unmusically, with $40m investment in CoDa

 
• By Pial Ganguli

As part of their strategic investment partnership, Domain Associates and RusnanoMedInvest (a subsidiary of Rusnano) have made their first joint investment of nearly $40 million into San Diego, California-based CoDa Therapeutics. The funds will be used by CoDa to "pursue late-stage clinical trials".

As part of their strategic investment partnership, Domain Associates and RusnanoMedInvest (a subsidiary of Rusnano) have made their first joint investment of nearly $40 million into San Diego, California-based CoDa Therapeutics. The funds will be used by CoDa to "pursue late-stage clinical trials".

In March, Domain, a large US healthcare-focused venture capital firm, and Rusnano, the Russian state-owned investor in high-tech industries, entered...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Dermatological

More from Therapeutic Category

ProKidney Pins Hopes On Accelerated Approval For Rilparencel

 
• By Alaric DeArment

After posting encouraging Phase II results, the company plans to meet with the US FDA about using data from an ongoing Phase III study for an accelerated approval.

Merck & Co.’s Verona Acquisition Marks A Return To Respiratory

 
• By Jessica Merrill

With the $10bn acquisition of Verona, Merck gains the marketed COPD drug Ohtuvayre, reentering respiratory, where it was once a leader with Singulair.

Lilly’s Kisunla Label Update Lowers ARIA-E Risk For Alzheimer’s Patients

 
• By Mandy Jackson

The updated US FDA label modifies dose titration based on TRAILBLAZER-ALZ 6, a study that showed a more gradual rise in dosing levels reduced ARIA-E incidence without reducing amyloid clearance.